Moderna's Cancer Vaccine Boosts Stock
Moderna's shares surged over 120% after announcing a collaboration with Merck to create a personalized cancer vaccine that showed promising results in tests. The company's stock later soared by nearly 180% following news of the vaccine's successful third-phase clinical trials.3 sourcesSee all sources